Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Meiss

Showing results (51-60 of 110) with videos related to

Pageof 11
Sort By:
Oncoimmunology|May 4, 2016
Vemurafenib and ipilimumab: A promising combination? Results of a case seriesJessica C Hassel, Sophia B Lee, Frank Meiss, et al.
Acta Dermato-Venereologica|June 20, 2023
Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis BullosaLaura Trefzer, Maria E Hess, Lena Scholten, et al.
Acta Dermato-Venereologica|November 9, 2013
Iatrogenic vitamin D deficiency in a patient with Gorlin syndrome: the conundrum of photoprotectionSabrina Gentzsch, Johannes S Kern, Stefan Loeckermann, et al.
Journal of Translational Medicine|December 12, 2022
Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunityZhen Zhang, David Rafei-Shamsabadi, Saskia Lehr, et al.
The Journal of Investigative Dermatology|October 22, 2017
Indoleamine 2,3-Dioxygenase Expression in Primary Cutaneous Melanoma Correlates with Breslow Thickness and Is of Significant Prognostic Value for Progression-Free SurvivalFelicia Rubel, Johannes S Kern, Kristin Technau-Hafsi, et al.
Pediatric Blood & Cancer|December 6, 2021
Combinatorial effects of azacitidine and trametinib on NRAS-mutated melanomaKlara-Maria Hanft, Ebrahem Hamed, Max Kaiser, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|November 22, 2017
Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomasMelanie C Föll, Matthias Fahrner, Christine Gretzmeier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2022
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective studyMartin Salzmann, Johannes Pawlowski, Carmen Loquai, et al.
Orphanet Journal of Rare Diseases|December 5, 2019
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosaAndrea Diociaiuti, Holger Steinke, Alexander Nyström, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 22, 2025
Real-world management of adjuvant systemic melanoma therapy: Multi-center survey of 51 DeCOG skin cancer centersMarkus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling, et al.
Pageof 11

Showing results (51-60 of 110) with videos related to

Sort By:
Pageof 11
Oncoimmunology|May 4, 2016
Vemurafenib and ipilimumab: A promising combination? Results of a case seriesJessica C Hassel, Sophia B Lee, Frank Meiss, et al.
Acta Dermato-Venereologica|June 20, 2023
Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis BullosaLaura Trefzer, Maria E Hess, Lena Scholten, et al.
Acta Dermato-Venereologica|November 9, 2013
Iatrogenic vitamin D deficiency in a patient with Gorlin syndrome: the conundrum of photoprotectionSabrina Gentzsch, Johannes S Kern, Stefan Loeckermann, et al.
Journal of Translational Medicine|December 12, 2022
Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunityZhen Zhang, David Rafei-Shamsabadi, Saskia Lehr, et al.
The Journal of Investigative Dermatology|October 22, 2017
Indoleamine 2,3-Dioxygenase Expression in Primary Cutaneous Melanoma Correlates with Breslow Thickness and Is of Significant Prognostic Value for Progression-Free SurvivalFelicia Rubel, Johannes S Kern, Kristin Technau-Hafsi, et al.
Pediatric Blood & Cancer|December 6, 2021
Combinatorial effects of azacitidine and trametinib on NRAS-mutated melanomaKlara-Maria Hanft, Ebrahem Hamed, Max Kaiser, et al.
Matrix Biology : Journal of the International Society for Matrix Biology|November 22, 2017
Identification of tissue damage, extracellular matrix remodeling and bacterial challenge as common mechanisms associated with high-risk cutaneous squamous cell carcinomasMelanie C Föll, Matthias Fahrner, Christine Gretzmeier, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2022
MEK inhibitors for pre-treated, NRAS-mutated metastatic melanoma: A multi-centre, retrospective studyMartin Salzmann, Johannes Pawlowski, Carmen Loquai, et al.
Orphanet Journal of Rare Diseases|December 5, 2019
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosaAndrea Diociaiuti, Holger Steinke, Alexander Nyström, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|November 22, 2025
Real-world management of adjuvant systemic melanoma therapy: Multi-center survey of 51 DeCOG skin cancer centersMarkus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling, et al.
Pageof 11